$AUPH as a holder of AUPH I also want to be bullish but let’s temper our expectations -Not first product on the market to treat LN -Six deaths from clinical trials (fairly low% , but still six deaths) -GSK which has a competing product already approved only has a market cap of $2.5b. The upside here isn’t as big as some of us are anticipating -a lot of the positive expectations have been priced in already in the $6 > $20 jump a year ago So while i do think this will go up on 22nd, I would manage expectations and some take profits.
3 Likes